Table 1.
SC-islets and human donor islets treated with TCDD ± hypoxia show variability for gene expression changes.
| CYP1A1 | HMOX1 | AHRR | ARNT | G6PC2 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell source | TCDD | Hypoxia | Crosstalk | TCDD | Hypoxia | Crosstalk | TCDD | Hypoxia | Crosstalk | TCDD | Hypoxia | Crosstalk | TCDD | Hypoxia | Crosstalk |
| SC-Islets | ↑ (41-fold) | ↑ (1.1-fold) | ✓ | - | ↑ (24-fold) | x | ↑ (6-fold) | - | x | ↑ (1.2-fold) | ↑ (1.2-fold) | x | ↓ | ↓ | ✓ |
| R425 - ♂ | ↑ (10-fold) | ↓ | ✓ | - | ↑ (2-fold) | ✓ | ↑ (1.3-fold) | - | ✓ | - | - | x | - | ↓ | x |
| R434 -♂ | ↑ (3-fold) | - | x | ↑ (1.4-fold) | ↑ (5-fold) | x | ↑ (2-fold) | - | x | ↑ (1.7-fold) | ↑ (1.7-fold) | x | ↑ (2-fold) | ↓ | x |
| R444 -♂ | ↑ (11-fold) | - | x | ↑ (2.5-fold) | ↑ (2.6-fold) | x | ↑ (3-fold) | - | x | ↑ (2-fold) | - | x | ↑ (2-fold) | - | x |
| R427 -♀ | ↑ (3-fold) | ↓ | x | - | ↑ (3-fold) | x | - | - | x | - | - | x | - | ↓ | x |
| R430 -♀ | ↑ (3-fold) | - | ✓ | - | ↑ (3-fold) | x | ↑ (1.1-fold) | - | ✓ | - | - | ✓ | - | ↓ | x |
| R461 -♀ | ↑ (15-fold) | ↑ (2-fold) | ✓ | - | ↑ (3-fold) | x | ↑ (2-fold) | - | x | - | - | x | - | ↓ | x |
A summary table of the main effects of TCDD (10 nM) ± hypoxia (1% O2) on SC-islets and human donor islets for expression of CYP1A1, HMOX1, AHRR, ARNT, and G6PC2. Bolded fold-increase indicates significance for TCDD or hypoxia treatments alone, compared with vehicle control.